Report cover image

Sickle Cell Disease with Vaso-Occlusive Crisis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Sep 30, 2022
Length 51 Pages
SKU # GMD17477739

Description

Sickle Cell Disease with Vaso-Occlusive Crisis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease With Vaso-Occlusive Crisis - Drugs In Development, 2022, provides an overview of the Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease With Vaso-Occlusive Crisis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease With Vaso-Occlusive Crisis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 4, 1 and 4 respectively.

Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

51 Pages
Introduction
Global Markets Direct Report Coverage
Sickle Cell Disease With Vaso-Occlusive Crisis – Overview
Sickle Cell Disease With Vaso-Occlusive Crisis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Sickle Cell Disease With Vaso-Occlusive Crisis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sickle Cell Disease With Vaso-Occlusive Crisis – Companies Involved in Therapeutics Development
Alfasigma SpA
Asklepion Pharmaceuticals LLC
Chugai Pharmaceutical Co Ltd
Cyclerion Therapeutics Inc
Global Blood Therapeutics Inc
GlycoMimetics Inc
Hartis Pharma SA
NicOx SA
Novartis AG
NuvOx Pharma LLC
Prolong Pharmaceuticals LLC
Sickle Cell Disease With Vaso-Occlusive Crisis – Drug Profiles
crizanlizumab – Drug Profile
crovalimab – Drug Profile
GMI-1687 – Drug Profile
HRT-002 – Drug Profile
inclacumab – Drug Profile
L-Citrulline – Drug Profile
naproxcinod – Drug Profile
NVX-508 – Drug Profile
olinciguat – Drug Profile
rifaximin DR – Drug Profile
Sanguinate – Drug Profile
Sickle Cell Disease With Vaso-Occlusive Crisis – Dormant Projects
Sickle Cell Disease With Vaso-Occlusive Crisis – Discontinued Products
Sickle Cell Disease With Vaso-Occlusive Crisis – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: GBT’s inclacumab receives U.S. FDA orphan drug and rare pediatric disease designations for the treatment of sickle cell disease
Oct 06, 2021: NICE recommends Novartis’ crizanlizumab for sickle cell disease treatment
Apr 16, 2021: TGA provides update on Adakveo
Dec 07, 2020: GlycoMimetics announces presentation of preclinical data on GMI-1687 at the ASH meeting
Nov 19, 2020: Novartis announces presentation on Adakveo at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
Oct 30, 2020: Novartis sickle cell medicine Adakveo approved in Europe to prevent recurrent vaso-occlusive crises
Oct 26, 2020: New pediatric and secondary endpoint data from rivipansel phase 3 RESET trial presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting
Jun 12, 2020: GlycoMimetics announces to present preclinical data on GMI-1687 at Sickle Cell Meeting
Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states
Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients
Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting
Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Sickle Cell Disease With Vaso-Occlusive Crisis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Products under Development by Companies, 2022
Table 4: Number of Products by Stage and Target, 2022
Table 5: Number of Products by Stage and Mechanism of Action, 2022
Table 6: Number of Products by Stage and Route of Administration, 2022
Table 7: Number of Products by Stage and Molecule Type, 2022
Table 8: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Alfasigma SpA, 2022
Table 9: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Asklepion Pharmaceuticals LLC, 2022
Table 10: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Table 11: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Cyclerion Therapeutics Inc, 2022
Table 12: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Global Blood Therapeutics Inc, 2022
Table 13: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by GlycoMimetics Inc, 2022
Table 14: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Hartis Pharma SA, 2022
Table 15: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by NicOx SA, 2022
Table 16: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Novartis AG, 2022
Table 17: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by NuvOx Pharma LLC, 2022
Table 18: Sickle Cell Disease With Vaso-Occlusive Crisis – Pipeline by Prolong Pharmaceuticals LLC, 2022
Table 19: Sickle Cell Disease With Vaso-Occlusive Crisis – Dormant Projects, 2022
Table 20: Sickle Cell Disease With Vaso-Occlusive Crisis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Sickle Cell Disease With Vaso-Occlusive Crisis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us